Halozyme Therapeutics reported $1.75M in Interest Expense on Debt for its third fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Interest Expense On Debt Change
Alnylam Pharmaceuticals ALNY:US $ 40.27M 6.86M
Amarin AMRN:US $ 0.39M 0.36M
Amgen AMGN:US $ 296M 15M
Arena Pharmaceuticals ARNA:US $ 1.03M 0.02M
Baxter International BAX:US $ 36M 1M
Cytokinetics CYTK:US $ 4.16M 0.09M
Eli Lilly And LLY:US $ 83.6M 3.3M
Esperion Therapeutics ESPR:US $ 13.65M 2.51M
Halozyme Therapeutics HALO:US $ 1.75M 0M
Immunogen IMGN:US $ 2.75M 0.83M
Intercept Pharmaceuticals ICPT:US $ 14.1M 1.51M
JAZZ PHA JAZZ:US $ 93.47M 23.65M
Mannkind MNKD:US $ 2.8M 0.38M
Nektar Therapeutics NKTR:US $ 12.8M 0.29M
Peregrine Pharmaceuticals PPHM:US 703K 461K
Pfizer PFE:US $ 325M 9M
Rigel Pharmaceuticals RIGL:US $ 1.32M 0.44M
United Therapeutics UTHR:US $ 4.6M 0.1M